Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,296 papers from all fields of science
Search
Sign In
Create Free Account
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Known as:
Metastatic Non-Squamous Non-Small Cell Lung Cancer
A non-squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
14 relations
Chest
EGFR Gene Mutation
EGFR gene
Epithelial Cells
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
A real-world analysis of non-small cell lung cancer patients treated with pembrolizumab or pembrolizumab in combination with pemetrexed and platinum.
Himani Agg
,
K. Winfree
,
Y. Zhu
,
C. Muehlenbein
2020
Corpus ID: 213666659
53Background: Pembrolizumab (Pembro) is used in first-line treatment of patients with metastatic non-squamous non-small cell lung…
Expand
Review
2019
Review
2019
Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer
J. H. Park
,
B. Kwon
,
+4 authors
Jae Cheol Lee
Journal of Cancer Research and Clinical Oncology
2019
Corpus ID: 169033341
PurposeBased on an exceptionally durable response to pemetrexed observed in some patients with metastatic NSCLC, the predictive…
Expand
2018
2018
A phase III, randomized, open-label, multicenter study of SHR-1210 (anti-PD-1 antibody) in combination with pemetrexed and carboplatin as first line therapy in subjects with advanced/metastatic non…
F. Wu
,
G. Gao
,
C. Zhou
,
X. Kang
,
Y. Zhou
Annals of Oncology
2018
Corpus ID: 57335174
2016
2016
A phase 1b study of famitinib plus docetaxel as 2nd line setting in patients with metastatic non-squamous non-small cell lung cancer and EGFR wild type.
Caicun Zhou
,
S. Ren
,
+8 authors
Yu-Chieh Yu
2016
Corpus ID: 81873257
e20603Background: This phase Ib study was designed to evaluate the safety and efficacy of famitinib plus docetaxel in previously…
Expand
2015
2015
Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first…
A. Kotsakis
,
N. Kentepozidis
,
+14 authors
V. Georgoulias
Lung Cancer
2015
Corpus ID: 43377313
2014
2014
A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
C. Dittrich
,
Z. Pápai-Székely
,
+7 authors
J. von Pawel
European Journal of Cancer
2014
Corpus ID: 8263898
2014
2014
P0066 A randomised phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or…
J.C. Yang
,
Keunchil Park
,
+7 authors
R. Nair
2014
Corpus ID: 71336025
2013
2013
Pemetrexed-induced anaphylaxis
B. Shah
,
Y. Hewett
Acta oncologica
2013
Corpus ID: 278739
Pemetrexed is a folate antimetabolite approved for the treatment of mesothelioma and locally advanced or metastatic non-squamous…
Expand
2009
2009
Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC).
N. Ferrer
,
M. Cobo
,
+7 authors
J. Torrego
Journal of Clinical Oncology
2009
Corpus ID: 26601809
e19023 Background: Bevacizumab (B), in addition to platinum-based chemotherapy, is indicated for 1st-line treatment of p with…
Expand
2008
2008
EGFR mutations and gefitinib sensitivity in patients with metastatic non-squamous non-small cell lung cancer
V. Moiseyenko
,
E. Imyanitov
,
+7 authors
F. Moiseyenko
2008
Corpus ID: 79231460
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required